Pierre Massion
Faculty Member
Last active: 1/11/2018

  1. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Deppen S, Putnam JB, Andrade G, Speroff T, Nesbitt JC, Lambright ES, Massion PP, Walker R, Grogan EL (2011) Ann Thorac Surg 92(2): 428-32; discussion 433
    › Primary publication · 21592456 (PubMed) · PMC3186439 (PubMed Central)
  2. What makes tight glycemic control tight? The impact of variability and nutrition in two clinical studies. Suhaimi F, Le Compte A, Preiser JC, Shaw GM, Massion P, Radermecker R, Pretty CG, Lin J, Desaive T, Chase JG (2010) J Diabetes Sci Technol 4(2): 284-98
    › Primary publication · 20307388 (PubMed) · PMC2864163 (PubMed Central)
  3. National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers. Patz EF, Caporaso NE, Dubinett SM, Massion PP, Hirsch FR, Minna JD, Gatsonis C, Duan F, Adams A, Apgar C, Medina RM, Aberle DR (2010) J Thorac Oncol 5(10): 1502-6
    › Primary publication · 20871260 (PubMed) · PMC2963472 (PubMed Central)
  4. DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Ocak S, Yamashita H, Udyavar AR, Miller AN, Gonzalez AL, Zou Y, Jiang A, Yi Y, Shyr Y, Estrada L, Quaranta V, Massion PP (2010) Oncogene 29(48): 6331-42
    › Primary publication · 20802517 (PubMed) · PMC4637980 (PubMed Central)
  5. Diagnostic characteristics of a serum biomarker in patients with positron emission tomography scans. Grogan EL, Deppen S, Pecot CV, Putnam JB, Nesbitt JC, Shyr Y, Rajanbabu R, Ory B, Lambright ES, Massion PP (2010) Ann Thorac Surg 89(6): 1724-8; discussion 1728-9
    › Primary publication · 20494018 (PubMed) · PMC3026702 (PubMed Central)
  6. Airway PI3K pathway activation is an early and reversible event in lung cancer development. Gustafson AM, Soldi R, Anderlind C, Scholand MB, Qian J, Zhang X, Cooper K, Walker D, McWilliams A, Liu G, Szabo E, Brody J, Massion PP, Lenburg ME, Lam S, Bild AH, Spira A (2010) Sci Transl Med 2(26): 26ra25
    › Primary publication · 20375364 (PubMed) · PMC3694402 (PubMed Central)
  7. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Qian J, Zou Y, Rahman JS, Lu B, Massion PP (2009) Mol Cancer Ther 8(1): 101-9
    › Primary publication · 19139118 (PubMed) · PMC3110728 (PubMed Central)
  8. Recurrent genomic gains in preinvasive lesions as a biomarker of risk for lung cancer. Massion PP, Zou Y, Uner H, Kiatsimkul P, Wolf HJ, Baron AE, Byers T, Jonsson S, Lam S, Hirsch FR, Miller YE, Franklin WA, Varella-Garcia M (2009) PLoS One 4(6): e5611
    › Primary publication · 19547694 (PubMed) · PMC2699220 (PubMed Central)
  9. Mass spectrometry-based proteomic profiling of lung cancer. Ocak S, Chaurand P, Massion PP (2009) Proc Am Thorac Soc 6(2): 159-70
    › Primary publication · 19349484 (PubMed) · PMC2674226 (PubMed Central)
  10. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Ocak S, Sos ML, Thomas RK, Massion PP (2009) Eur Respir J 34(2): 489-506
    › Primary publication · 19648524 (PubMed) · PMC4648268 (PubMed Central)